[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
March 3, 2010

Losing the Opportunity to Study Influenza Drugs

Author Affiliations

Author Affiliations: Division of Clinical Pharmacology, Department of Medicine (Dr Meyerhoff), Departments of Medicine, Pharmacology and Molecular Sciences, and Pediatrics (Dr Lietman), Johns Hopkins University School of Medicine, Baltimore, Maryland; and GexGroup Inc, Washington, DC (Dr Meyerhoff).

JAMA. 2010;303(9):878-879. doi:10.1001/jama.2010.234

Shortly after 2009 influenza A(H1N1) emerged, we advocated for real-time clinical trials to make use of the rare opportunity—and an ethical imperative—to study influenza drugs while the pandemic is ongoing.1 Tran et al2 further emphasized this need for prospective clinical trials during the outbreak. Persistent gaps in knowledge about drugs to treat influenza and the recent decision by the US Food and Drug Administration (FDA) to issue an Emergency Use Authorization for peramivir,3 an unapproved drug, make this need even more acute.

First Page Preview View Large
First page PDF preview
First page PDF preview
×